beat top line bottom line
management report minim impact rev lower
guidanc base impact new start
potenti neg shift reimburs mix see
updat prudent pt portola addit
top line bottom line total revenu ahead
driven soliri ultomiri management note inventori pull-
base management updat guidanc note
valu includ portola acquisit total revenu guidanc
total soliris/ultomiri revenu
guidanc metabol franchis
revenu guidanc guidanc
revenu sg guidanc
revenu oper margin guidanc
adjust ep guidanc revis
guidanc base medic center across world gradual reopen
start juli
takeaway call impact management report rel
small impact sale note slow new patient start lower
complianc extend time initi given rise unemploy
management expect increas proport medicar payer current us
make revenu medicar part
soliris/ultomiri management report acceler ultomiri convers
particularli hotspot management report convers pnh
patient note reiter ahu on-track convers
within two year patient us receiv soliri gmg
nmosd management believ ultomiri could penetr moder sever
gmg patient expand market opportun
 management initi phiii trial test ultomiri hospit patient
sever pneumonia acut respiratori distress primari
endpoint overal surviv day base encourag anecdot
evid patient treat soliri
 unit state america
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
play role treat base elev acut patient
increas report blood clot advanc patient management decid
incorpor ultomiri rather inhibitor renal basket
studi management longer plan test ultomiri ppm base
retrospect clinic biomark data complet enrol
phiii trial test wilson diseas data on-track
releas management expect interim data phii trial
test danicopan management plan re-initi
phii trial test waiha management note impact
enrol base desir switch subq formul
rather iv base competit landscap base result
phi trial management expect initi phii trial test subq formul
gmg note management previous report issu
formul initi comment portola
acquisit found
fine covid impact modest accur reflect guidanc
good news convers ultomiri remain on-track even ahead
also pipelin progress franchis remain strong subq
addit indic on-track howev diversif strategi remain
key investor debat fcrn delay long-term valu
portola remain question thu expect remain current
trade rang greater visibl strategi beyond
ultomiri convers soliri neurolog launch pipelin drive risk/reward
deriv pt discount cash ow analysi assum wacc
termin growth rate revenu driver model pnh sale ahu sale mg
sale nmo sale strensiq sale kanuma sale
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
may gure approxim risk-neutr probabl stock reach beyond scenario
price either three-month one-year time view explan option probabl methodolog
ahu mg penetr ultomiri
ahu mg penetr ultomiri
succe signic share convers
succe signic share convers
standard care pnh ahu nmo
mg pnh sale
peak ww ahu sale
peak assum strensiq
kanuma continu launch
sale respect
assum peak ww andexxa sale
soliri meaning growth pnh ahu
soliri meaning growth pnh ahu
gmg
gmg ultomiri succe modest
solid convers ultomiri long-term
durabl complement franchis
assum gmg nmo meaning
contribut sale assum strensiq
kanuma continu launch
sale respect
see soliri longev incorpor
competit price pressur
assum peak ww andexxa sale
equal-weight believ
despit strong execut management consensu
need see greater revenu divers
away franchis
increas termin multipl
believ initi ultomiri execut
strong pnh expect similar
transit ahu see option
subcutan neurolog indic
expect potenti posit
develop pipelin believ
management undertak organ rebuild
compani take time drive new
view descript risk reward theme
kanuma achiev minim sale
kanuma achiev minim sale bear
case assum soliri fail gain label
expans soliri face signic
headwind biosimilar
proprietari competit divers
strensiq kanuma minim
initi phii trial pnh
init phii studi waiha iv
initi limit dose-rang studi ultomiri adult
children hsct-tma
potenti launch pnh ultomiri mg/ml
administr pnh/ahu
ultomiri mg/ml launch pnh
view explan region hierarchi
research highest favor quintil
soliri pnh ahu mg growth could fail
meet expect
strensiq and/or kanuma fail captur market
share convers soliri ultomiri
project
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
inform opinion research prepar co llc and/or and/or morgan
stanley mexico de bolsa de and/or canada limit use disclosur section includ morgan
stanley co llc mexico de bolsa de canada limit affili
necessari
import disclosur stock price chart equiti rate histori regard compani subject report pleas see morgan
stanley research disclosur websit www morganstanley com/researchdisclosur contact invest repres
research broadway attent research manag new york ny usa
valuat methodolog risk associ recommend rate price target referenc research report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
follow analyst herebi certifi view compani secur discuss report accur express
receiv receiv direct indirect compens exchang express specif recommend view report matthew
unless otherwis state individu list cover page report research analyst
morgan stanley research publish accord conflict manag polici avail
www morganstanley com/institutional/research/conflictpolici portugues version polici found www morganstanley com br
import regulatori disclosur subject compani
